Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis.
We have recently reported the accumulation of oligoclonal activated T cells in the spontaneously developed autoimmune pancreatitis in aly/aly mouse. In this study, we examined the effects of FK506 in this mouse model in preventing autoimmune pancreatitis and investigated its action on calcium signalling apoptosis of alymphoplasia (aly) lymphocytes in vitro. Mice were treated with FK506 from 8 to 25 weeks of age. At the age of 15 weeks, minimal mononuclear cell infiltration was observed in the pancreas in both the FK506 treated group and the control group. Furthermore, a marked cell infiltration associated with destruction of acini and partial fatty changes were observed in 25-week-old control mice. In contrast, FK506 treated mice showed almost no tissue destruction or mononuclear cell infiltration at the age of 25 weeks. Furthermore, at 15 weeks of age, most mononuclear cells in FK506-treated mice were TUNEL positive, whereas only a few were positive in control mice. This augmentation of T cell apoptosis by FK506 was confirmed using naive splenocytes activated by PMA and ionomycin in vitro. Finally, a suppressive effect of FK506 on Bcl-2 production but not on Bax production was confirmed by Western blotting. This unique effect of FK506 on the augmentation of T cell apoptosis is probably one of the mechanisms explaining its beneficial effect on aly autoimmune pancreatitis.
Hashimoto
Y
Y
Department of Surgery II, Nagasaki University School of Medicine, Nagasaki City, Nagasaki, Japan.
Matsuoka
N
N
Kawakami
A
A
Tsuboi
M
M
Nakashima
T
T
Eguchi
K
K
Tomioka
T
T
Kanematsu
T
T
D000818:Animals; D017209:Apoptosis; D001327:Autoimmune Diseases / Q000188:drug therapy; D020013:Calcium Signaling; D002478:Cells, Cultured; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D010195:Pancreatitis / Q000188:drug therapy; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D016559:Tacrolimus / Q000494:pharmacology* / Q000627:therapeutic use; D051028:bcl-2-Associated X Protein
C494827:Bax protein, mouse; D007166:Immunosuppressive Agents; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011948:Receptors, Antigen, T-Cell; D051028:bcl-2-Associated X Protein; D016559:Tacrolimus